Clinical Trial Update: Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations [NA]

View source ↗

Summary

AstraZeneca is implementing standardized early identification and diagnosis strategies for transthyretin amyloidosis in high-risk populations, with a focus on t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy
• Transthyretin Amyloidosis

Snippet

Sponsor: AstraZeneca | Conditions: ATTR-CM | NA | Status: NOT_YET_RECRUITING